PanV, Inc. is a biotechnology company spun out of the Iwasaki Laboratory at Yale University developing a novel class of antibody therapeutics that target conserved post-translational modifications (PTMs) derived from host cells and shared across diverse viral families. This unique mechanism enables PanV to deliver broad-spectrum antiviral activity and novel immuno-oncology solutions with a single therapeutic approach. Our lead programs address two high-value markets:
1. HERV+ Cancers: Leveraging the reactivation of endogenous retroviruses in tumors to create a new class of targeted immunotherapies.
2. Transplant Medicine: Providing durable, pan-viral protection for immunocompromised patients vulnerable to infections.
Unlike traditional antivirals that target mutable viral proteins, PanV antibodies recognize stable, host-derived PTMs present on virions. This strategy offers a pan-viral solution effective against retroviruses, herpesviruses, coronaviruses, and influenza.
With foundational IP and strong academic validation, PanV seeks to transform the treatment of virus-associated cancers and viral infections - unlocking significant clinical and commercial value.
Company Details
- Founded
- -
- Address
- New Haven, Ct, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- CATTLEytics.
- HQ
- New Haven, CT
Panv, Inc. Questions
Panv, Inc.'s LinkedIn profile is https://www.linkedin.com/company/panv
Panv, Inc.'s industry is
Biotechnology Research
Panv, Inc.'s top competitors are
Rigimmune Inc.,
London Longevity Network,
Santo Therapeutics,
Cattleytics,
Ioniks,
Rho Bio,
Xanadu Bio,
New England Venture Capital Association,
Ikonisys,
Getseen Ventures.
Panv, Inc.'s categories are Biotechnology Research
Panv, Inc.'s founding year is 2023
